Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Abstract
We performed a win ratio (WR) analysis of REPRIEVE, a randomized trial of pitavastatin vs placebo for cardiovascular disease in people with human immunodeficiency virus to assess robustness to event severity. WR aligns with primary findings and provides insight into pitavastatin protections: persistent advantage on death, stroke, and myocardial infarction. Clinical Trials Registration . NCT02344290.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.